SBIR/STTR Research Award
Video observed therapy to enhance flexibility and reduce in-person visits for patients treated with methadone in a multi-site opioid treatment program
Award amount
$1,964,306Program and phase
SBIR · Phase IIAward year
2023Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- EMOCHA MOBILE HEALTH INC.
- Proposal award date
- 2023-08-01
- Contract end date
- 2026-07-31
- UEI
- FHWGEP6NNLG1
- Solicitation number
- PA22-177
- Topic code
- NIDA
Research abstract
Methadone is an effective treatment for opioid use disorder (OUD) yet historically the care delivery model requires directly-observed therapy (DOT) at opioid treatment programs which is a barrier to clients. Many factors ultimately led to the revision of regulations, paving the way for more flexible models of care. Our prior Phase I research demonstrated the feasibility, safety, and acceptability of an innovative mobile health platform to provide asynchronous, video DOT and to screen for symptoms of disease for patients treated for OUD with methadone; this proposal aims to test the implementation of video direct observe therapy (video-DOT) for methadone across a large, multisite OTP organization via a Hybrid Type 2 Effectiveness Implementation study with stepped wedge cluster randomized trial design.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness)
- Evaluation of a mobile app-based video Directly Observed Therapy (video DOT) intervention for medication adherence in pediatric heart transplant patients
- Feasibility of mHealth technology-enabled service for remote observed therapy of methadone and COVID-19 screening for patients in an opioid treatment program
- Development and Evaluation of a Mobile Directly Observed Therapy Smartphone App for Immunosuppressive Adherence in Transplant Patients
- Development and Evaluation of a Mobile Directly Observed Therapy Smartphone App for Immunosuppressive Adherence in Transplant Patients
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)
Research funding history
10 SBIR/STTR records share this UEI (2015–2023). Reported award amounts total $11,616,632. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services